News - Sandoz

Filter

Current filters:

Sandoz

Popular Filters

1 to 25 of 52 results

Novartis 2nd-qtr sales and net profit up but miss analysts’ forecasts

Novartis 2nd-qtr sales and net profit up but miss analysts’ forecasts

17-07-2014

Switzerland’s Novartis – now the world’s largest pharmaceutical company by sales - this morning…

AlconFinancialNovartisPharmaceuticalSandoz

Shire gets positive ruling on Vyvanse patents from US district court

25-06-2014

Ireland-headquartered drugmaker Shire, which is defending itself from a $46 billion unsolicited bid from…

ActavisAmneal PharmaLegalMylanNeurologicalPatentsPharmaceuticalRoxaneSandozShireUSAVyvanse

Novartis 1st-qtr net profit flat, sales shy of forecasts

Novartis 1st-qtr net profit flat, sales shy of forecasts

24-04-2014

Swiss drug major Novartis posted a solid set of first-quarter 2014 financials this morning, showing that…

AlconFinancialNovartisPharmaceuticalSandoz

Novartis appoints Jeff George as Division Head, Alcon and Richard Francis as Division Head, Sandoz

Novartis appoints Jeff George as Division Head, Alcon and Richard Francis as Division Head, Sandoz

22-04-2014

Swiss drug major Novartis has announced the appointment of Jeff George as Division Head of Alcon and…

AlconBoardroomNorthern EuropeNovartisPharmaceuticalSandoz

EGA Biosimilars: Prescribers must be encouraged to use biosimilars

EGA Biosimilars: Prescribers must be encouraged to use biosimilars

07-04-2014

Uptake of biosimilars in Europe has increased as a result of member states’ policies, according to…

BiosimilarsEuropeFilgrastimInterviewsMarkets & MarketingRegulationSandoz

Tacrolimus Sandoz gets sole subsidy supply status in New Zealand

Tacrolimus Sandoz gets sole subsidy supply status in New Zealand

07-03-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC has decided to award immunosuppressant drug…

Asia-PacificGenericsImmunologicalsMarkets & MarketingNew ZealandNovartisPricingSandozTacrolimus Sandoz

Sandoz to commercialize Taiwan Liposome’s antifungal

Sandoz to commercialize Taiwan Liposome’s antifungal

19-12-2013

Taipei-based biopharmaceutical company Taiwan Liposome Company has entered into a collaboration agreement…

Amphotericin BAntibiotics and Infectious diseasesAsia-PacificGenericsLicensingNovartisSandozTaiwan Liposome

Sandoz launches Phase III trial of biosimilars of AbbVie’s Humira

Sandoz launches Phase III trial of biosimilars of AbbVie’s Humira

19-12-2013

Sandoz, the generics unit of Swiss drug major Novartis (NOVN: VX), has initiated a Phase III clinical…

AbbVieBiosimilarsHumiraImmunologicalsNorthern EuropeResearchSandoz

Sandoz receives Danish approval for AirFluSal Forspiro inhaler

Sandoz receives Danish approval for AirFluSal Forspiro inhaler

19-12-2013

Swiss drug major Novartis' (NOVN: VX) generics unit Sandoz has received Danish marketing authorization…

DenmarkPharmaceuticalRegulationRespiratory and PulmonarySandozVectura

Apricus expands Vitaros deal with Novartis unit

Apricus expands Vitaros deal with Novartis unit

16-12-2013

USA-based Apricus Biosciences has expanded its exclusive license agreement with Hexal AG, an affiliate…

Apricus BioscienceEuropeLicensingMen's HealthNovartisPharmaceuticalSandozVitaros

EC fines J&J and Novartis 16 million euros over fentanyl pay-for-delay deal

EC fines J&J and Novartis 16 million euros over fentanyl pay-for-delay deal

11-12-2013

The European Commission has imposed fines of 10.8 million euros ($14.8 million) on the US health care…

EuropefentanylFinancialJohnson & JohnsonNeurologicalNovartisPatentsPharmaceuticalSandoz

Sandoz in deal to market authorized generic of Shire’s Adderall XR in USA

Sandoz in deal to market authorized generic of Shire’s Adderall XR in USA

03-12-2013

UK drugmaker Shire says that its subsidiary Shire US Inc has entered into an agreement to supply an authorized…

Adderall XRGenericsLicensingNeurologicalNorth AmericaNovartisSandozShire

Sandoz appeals US court decision on AzaSite patent

Sandoz appeals US court decision on AzaSite patent

06-11-2013

US ophthalmic care specialist InSite Vision says that Sandoz Inc, the US generics unit of Swiss drug…

AzaSiteGenericsInSite VisionLegalNorth AmericaNovartisOphthalmicsPatentsSandoz

Novartis third quarter results driven by strong sales despite generic competition

Novartis third quarter results driven by strong sales despite generic competition

22-10-2013

Novartis has announced strong sales performance in its third quarter results, released today.

DiovanEuropeFinancialNorth AmericaNovartisPharmaceuticalSandozZometa

Apricus ED drug gains national phase approval in Germany

09-10-2013

Germany's Federal Institute for Drugs and Medical Devices has granted national phase approval for USA-based…

Apricus BioscienceEuropeMen's HealthPharmaceuticalRegulationSandozVitaros

Avanir agrees settlement with Sandoz over Nuedexta

14-08-2013

US drugmaker Avanir Pharmaceuticals (Nasdaq: AVNR) has entered into a settlement agreement with Swiss…

Avanir PharmaceuticalsGenericsLicensingNeurologicalNorth AmericaNuedextaPharmaceuticalSandoz

Proposal for a sole supply arrangement for fentanyl patches in New Zealand

08-07-2013

New Zealand's Pharmaceutical Management Agency, PHARMAC, is seeking feedback on a proposal to list a…

Asia-PacificfentanylFentanyl SandozNeurologicalNovartisPharmaceuticalPricingRegulationSandoz

Sandoz initiates Ph III trial for biosimilar Enbrel

24-06-2013

Swiss drug major Novartis' (NOVN: VX) generics unit Sandoz has initiated a major Phase III clinical trial…

AmgenAnti-Arthritics/RheumaticsBiotechnologyDermatologicalsEnbrelGenericsNovartisResearchSandoz

Actavis and Kissei file law suits against Sandoz and Hetero over Rapaflo patent

19-06-2013

USA-based Actavis (NYSE: ACT), itself predominantly a generic drug marketer, and Japan's Kissei Pharmaceutical…

ActavisGenericsHetero GroupMen's HealthNorth AmericaNovartisPatentsPharmaceuticalRapaflo CapsulesSandoz

1 to 25 of 52 results

Back to top